European Journal of Integrative Medicine
Volume 2, Issue 2 , Pages 63-69 , June 2010

Durable tumour responses following primary high dose induction with mistletoe extracts: Two case reports

  • M. Orange

      Affiliations

    • Park Attwood Clinic, Trimpley/Bewdley, Worcestershire DY12 1RE, UK
    • Corresponding Author InformationCorresponding author.
    • ,
  • M. Fonseca

      Affiliations

    • Park Attwood Clinic, Trimpley/Bewdley, Worcestershire DY12 1RE, UK
    • ,
  • A. Lace

      Affiliations

    • Park Attwood Clinic, Trimpley/Bewdley, Worcestershire DY12 1RE, UK
    • ,
  • H.B. von Laue

      Affiliations

    • Onkologische Schwerpunktpraxis Am Eichhof 30, D-75223, Niefern-Oeschelbronn, Germany
    • ,
  • S. Geider

      Affiliations

    • Camphill Medical Practice, Bieldside, Aberdeen, UK

Received 11 January 2010 ,Revised 16 March 2010 ,Accepted 7 April 2010.

References 

  1. In:  Büssing A editors. Mistletoe. The genus viscum. Amsterdam: Hardwood Academic Publishers; 2000;ISBN 90-5823r-r092-9
  2. Büssing A. Immune modulation using mistletoe (Viscum album L.) extracts iscador influencing cell function through subcutaneous and intravenous application. Arzneim.-Forsch./Drug Res. 2006;56(6a):508–515
  3. Matthes H, Buchwald D, Kroez M, Schad F. Integrative Therapie-moeglichkeiten des inoperablen Pankreaskarzinoms—eine Uebersicht. Dtsch Zeitsch Onkologie. 2008;40(3):106–110
  4. Kienle GS, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res. 2007;12(3):103–119
  5. Debus M. Intralesional mistletoe therapy. Der Merkurstab. 2009;62(4):304–305
  6. Lemos B, Nghiem P. Merkel cell carcinoma: more deaths but still no pathways to blame. J Invest Dermatol. 2007;127:2100–2103
  7. Pectasides D, Pectasides M, Economopoulos T. Merkel cell cancer of the skin. Ann Oncol. 2006;17:1489–1495
  8. Garneski KM, Nghiem P. Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy. J Am Acad Dermatol. 2007;57:166–169
  9. Sais G, Admella C, Solerà T. Spontaneous regression in primary cutaneous neuroendocrine (Merkel cell) carcinoma: a rare immune phenomenon?. J Eur Acad Dermatol Venereol. 2002;16:81–94
  10. Büssing A, Schietzel M. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res. 1999;19:23–28
  11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst. 2000;92:205–216
  12. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, et al. Common toxicity criteria: version 2.0. Int J Radiat Oncol Biol Phys. 2000;47(1):13–47
  13. American Cancer Society . Breast cancer facts & figures 2007–2008. Atlanta: American Cancer Society Inc.; 2007;
  14. Carmichael AR, Bendall S, Lockerbie L, Prescott R, Bates T. The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol. 2002;28:388–391
  15. Irvine T, Allen DS, Gillett C, Hamed H, Fentiman IS. Prognosis of synchronous bilateral breast cancer. Br J Surg. 2009;96:376–380
  16. Challis GB, Stam HJ. The spontaneous regression of cancer. Acta Oncol. 1990;29(5):545–550
  17. den Brok MHMGM, Sutmuller RPM, van der Voort R, Bennink EJ, Carl G, Figdor CG, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 2004;64:4024–4029
  18. Crittenden MR, Thanarajasingam U, Vile RG, Gough MJ. Intratumoral immunotherapy: using the tumour against itself. Immunology. 2005;114:11–22
  19. Sanchez-Perez L, Gough M, Qiao J, Thanarajasingam U, Kottke T, Ahmed A, et al. Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells. Gene Ther. 2007;14:998–1009
  20. Thong PS-P, Ong K-W, Goh NS-G, Kho K-W, Manivasager V, Bhuvaneswari R, et al. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol. 2007;8:950–952
  21. Dr. med Kraft . Praktische Erfahrungen ueber die Behandlung der Krebskrankheit mit Mistelextrakten. Muench Med Wschr. 1940;50:1395–1399
  22. Röseler W-B. Zur Behandlung inoperabler Carcinome. Der Krankenhausarzt in Wissenshaft, Recht und Wirtschaft. 1950;3(3):125–127
  23. Scheffler A, Mast H, Fischer S, Metelmann HR. Komplette Remission eines Mundhöhlenkarzinoms nach alleiniger Mistelbehandlung (Complete remission of oro-paryngeal carcinoma after sole mistletoe treatment), In:  Scheer R,  Becker H,  Berg PA editor. Grundlagen der Misteltherapie-Aktueller Stand der Forschung und klinische Anwendung. Stuttgart: Hippokrates Verlag; 1996;p. 453–466
  24. Stumpf C, Ramirez-Martinez S, Becher A, Stein GM, Biissing A, Schietzel M. Intratumorale Mistelapplikation bei stenosierendem Rezidiv eines Cardia-Carzinoms. Erfahrungsheilkunde. 1997;46:509–513
  25. Matthes H. Intralesionale Mistelinjektionen in Lebermetastasen bei kolorektalem Karzinom und in das primaere Hepatozellulaer Karzinom (HCC) [Abstract]. Merkurstab. 1997;50:41
  26. Mahfouz M, Chaleb H, Hamza MR, Fares L, Moussa L, Muostafua A, et al. Multicenter open labeled clinical study in advanced breast cancer patients. A preliminary report. J Egypt Nat Cancer Inst. 1999;11(3):221–227
  27. Nabrotzki M, Scheftler A. Komplette Remission nach intratumoraler Misteltherapie eines Duodenum-Karzinoni-Rezidivs. In:  Scheer R,  Bauer R,  Becker H,  Berg PA,  Fintelmann V editor. Die Mistel in der Tumortherapie. Crundlagenforschung und Klinik. Essen: KVC Verlag; 2001;p. 413–422(in German)
  28. Matthes H, Buchwald D, Kroez M, Schad F. Integrative Therapiemoeglichkeiten des inoperablen Pankreaskarzinoms. Dtsch Ztschr f Onkologie. 2008;40:106–110
  29. Coley-Nauts HC, Fowler G, Bogatko FH. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man. Acta Med Scand. 1953;145:5–102
  30. Hobohm U. Fever therapy revisited. Br J Cancer. 2005;92:421–425
  31. Decker WK, Safdar A. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine Growth Factor Rev. 2009;20(4):271–281
  32. Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia. 2001;17:1

PII: S1876-3820(10)00027-2

doi: 10.1016/j.eujim.2010.04.001

European Journal of Integrative Medicine
Volume 2, Issue 2 , Pages 63-69 , June 2010

Article Tools

* Image Usage & Resolution